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Abstract 
Introduction 
The cross talk between infectious agents and the human host are far from being 
completely understood and from both sides (host and infectious agents) changes along times 
are to be expected. Biological therapies for inflammatory immune-mediated diseases, alone or 
in association with (or following) immunomodulators, changed the perspective of dealing with 
these pathologies and brought a new paradigm of its treatment. Opposite glucosteroids and 
the old immunomodulators, such as methotrexate and thiopurines inhibitors, biological 
therapies act in specific and very restrict points of the immune system, and unexpected 
immune answers may arise. The main concerns regarding these therapies are the potential 
induction of auto immunity, neoplastic diseases and infection. In the field of biologics, 
infection behaviour in different, and sometimes unexpected ways, compared with the non-
immunosuppressed host. Also, as these therapies decrease or suppress the immune answer, 
the risk of infection rises. Tuberculosis (TB) associated with anti-tumor necrosis factor alfa 
(anti-TNFα) therapies and progressive multifocal leukoencephalopathy (PML) associated with 
the prescription of natalizumab, an humanized monoclonal antibody against the cell adhesion 
molecule α4-integrin, were milestones of the infectious risk of these new therapies. As there 
are still gaps in the knowledge we are in need of a deeper understanding of the infectious risk 
and the behaviour of infection under biological therapies to increase patient safety. 
Among biological drugs, anti-TNFα enabled a large field of study, as they are 
prescribed for the treatment of several pathologies since 1998. Granulomatous and 
intracellular infections are of special concern in patients treated with anti-TNFα because the 
capacity of containing infection in the case of granulomatous infections is lost and the defence 
against intracellular agents weakened. Despite this knowledge, several questions need further 
research, such as: (i) how do TB behaviour in patients treated with anti-TNFα in terms of 
clinical manifestations, diagnosis and response to treatment and how different is from the non 
immunosuppressed population? (ii) is the TB incidence in a country such as Portugal, that has 
an intermediate risk of the disease, enough to justify a different management of latent TB 
screening before and during biologics from countries with a low and very low TB incidence? 
(iii) which are the best tests for the diagnosis of latent TB to avoid false negative results? (iv) 
should we retest for TB and how during anti-TNFα and other biological therapies that have the 
risk of reactivation of Mycobacterium tuberculosis? (v) how can the global  infectious risk 
associated with these therapies be better mitigated? 
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Objectives and Methods 
Considering the existing gaps of knowledge and clinical needs, the  work carried out in 
the scope of the present thesis concerning infection in adults with immune-mediated 
inflammatory diseases, had four major objectives: the first one was to investigate TB - active 
disease  and its prevention in patients treated with anti -TNFα;  the second and third objectives 
were the study of other granulomatous and intracellular severe infections diagnosed in 
patients treated with anti-TNFα and immunomodulators, namely invasive listeriosis,  
nocardiosis and disseminated herpes virus infection; the fourth main objective was focused on 
infection prevention in patients under immunomodulatory and biological therapy, and ways to 
reduce the risk of infection under these therapies, contributing to increase drug safety and 
patient well-being. The cohort studied were adult patients suffering from inflammatory 
immune-mediated diseases and treated at Centro Hospitalar S. João, Porto, Portugal for the 
last 16 years. Retrospective, prospective and descriptive methods were applied in this study. 
The criteria for latent TB diagnosis tests was based on the positivity of a TST or/and a specific 
interferon gamma release assay’s (IGRA) test. 
To attain the first objective, the burden of active TB in this cohort of Portuguese 
patients under anti-TNFα therapy and the safety of anti-TNFα reintroduction after TB 
treatment were assessed. Then the work was focused on latent TB and two prospective studies 
were done. In the first, the sensitivity and specificity of the TST compared with T-SPOT.TB and 
Quantiferon Gold in-Tube test (QFT-GIT) - before or in the switch of anti-TNFα therapy - was 
studied in patients with inflammatory bowel diseases (IBD). In the second study, a serial 
screening for latent TB in patients under anti-TNFα along 26 months was done.   
Concerning the second objective, two cases of invasive listeriosis in the cohort of anti-
TNFα and or immunomodulated IBD treated patients were reviewed, followed by a literature 
review. Also two cases of a puzzling and repeated stool isolation of Nocardia nova, in patients 
suffering from inflammatory bowel disease under immunomodulators were analysed and a 
literature review of the disease in immunosuppressed patients was done.   
To attain the third objective a disseminated cutaneous herpes virus infection and a 
severe varicella in patients under immunomodulators plus, respectively, steroids and anti-
TNFα therapy were presented and confronted with a literature review.  
Finally, the fourth main objective was attained through the development of a practical 
approach to prevent infection in patients suffering from immune-mediated inflammatory 
diseases. This approach had a rational and was based on different recommendations from 
several authors that we adapted to the follow up of this cohort.  
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Results 
Regarding the study that addressed active TB, 25 TB cases from 765 patients treated 
with anti-TNFα drugs among 2001-2012 were reviewed. The estimated incidence of TB per 
100,000 patient-year of anti-TNFα prescription was 1337, 792 and 405 for those under 
infliximab, adalimumab and etanercept, respectively. Sixty per cent of the patients had extra-
pulmonary TB. Seventeen patients from the 25 were screened for latent TB before anti-TNFα: 
13 were negative and four positive. Three from these four patients were treated with 
isoniazid. Compared with a control group of community-acquired TB matched for sex, age and 
data of diagnosis, were more frequent in our cohort extra-pulmonary TB, fever on 
presentation and less positivity of direct microbiological exams; although the outcome of TB  
was not worse than in the general population. 
Lately, concerning the restart of anti-TNFα after TB, from 28 patients with TB, eight 
restarted anti-TNFα therapy: five have done so after and three during TB treatment. With a 
follow-up period of more than 2.5 years no recurrence of TB was verified. 
Facing TB prevention a prospective screening of TB in 250 patients with IBD about to 
start or switch anti-TNFα therapy was done. The diagnosis of latent TB was done in 29 % of 
them. We found TST had an overall higher sensitivity (81 vs. 35%) and a higher Negative 
Predictive Value (93% vs. 80%) when compared to QFT-GIT irrespective of the presence and 
kind of backbone immunosuppressive therapy. The concordance between both tests was 
weak. 
Another study concerning the serial screening for TB in 46 IBD patients under 
infliximab (after a negative screening before anti-TNFα), was performed six times across 26 
months, using T-SPOT.TB, TST and, for three screenings points, also QFT-GIT. Sixteen (29%) 
patients turned positive at least in one test (T.SPOT-TB, QFT-GIT or TST). The TST had the 
highest sensitivity, followed by T-SPOT.TB. Male patients and patients with long duration of 
IBD converted more frequently TB tests; test results were not concordant and positive IGRA’s 
results were not reproduced in the following screenings and its results were close to the cut-
off values. From the 16 patients 15 were treated with isoniazid; no cases of active TB were 
elicited. 
Concerning other granulomatous infection under anti-TNFα, two cases of invasive 
listeriosis (meningitis) were diagnosed and treated in patients with ulcerative colitis under 
infliximab; one of them was infected with human immunodeficiency virus (HIV). Both had a 
good outcome without sequelae and one restarted infliximab. 
From two IBD no symptomatic patients, treated with azathioprine and pulses of steroids, a 
pathogenic Nocardia, Nocardia nova, was isolated in several samples of stool; cutaneous and 
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invasive disease were excluded. One patient was treated with cotrimoxazole during the first 
three months of anti-TNFα introduction. The concern is that this colonization may disseminate 
and cause disease under deeper immunosuppression. This clinical situation was followed by a 
literature review of Nocardiosis in patients under immunomodulators and biologics. 
In the setting of herpes virus infection, a severe disseminated cutaneous herpes 
simplex infection was diagnosed in a young patient suffering from Crohn’s disease that was 
treated with steroids and azathioprine. She had a good outcome after acyclovir treatment.  
In a young male with Crohn’s disease treated with azathioprine and infliximab, a severe 
varicella that required inotropic support and mechanical invasive ventilation was described. 
The patient was discharged without remarkable sequelae and restarted anti-TNFα. In both 
situations a review of the literature concerning the disease in immunosuppressed patients was 
done.   
Related to the fourth objective a practical protocol of screening, infection prevention 
(including immunizations) and counselling in patients about to star biologics or 
immunomodulators due to an auto- inflammatory immune-mediated disease was elaborated 
and tested in this cohort.  
 
Conclusions 
In the combination between anti-TNFα therapies (alone or in association with 
immunomodulators) and infection, in the studied cohort, TB was the biggest concern and 
extra-pulmonary and disseminated forms were more common than in the general population, 
although TB outcome was not worse than in the general population. Reintroduction of anti-
TNFα therapies after or during TB treatment was safe. Concerning latent TB screening before 
anti-TNFα therapy, we found that TST remains important due to a higher sensitivity compared 
with IGRA’s tests even in patients under immunosuppressive therapies. On the setting of TB 
screening during anti-TNF α prescription, subject to much more debate, our results showed 
also higher sensitivity of TST and conversion and reversion of IGRA’s results that were closed 
to the cut-off values; thus, the suggestion is to screen regularly in the first years of prescription 
and in a tailor based way, according to perceived TB risk. Against the actual mainstream, 
probably would be advisable to maintain the TST before better tests for latent TB diagnosis 
become available. 
There is also risk of other severe granulomatous and intracellular infections, as we 
have diagnosed in our cohort, especially on the association of steroids with 
immunomodulators or biologics, and the risk of infection may be even partially unknown for 
the most recent therapies, so surveillance of patients under these therapies is crucial. 
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Regarding the real risk of infection as we found in the treated cohort, counselling 
screening and prophylaxis, including immunization, before biologics and immunomodulators is 
appropriate to mitigate the risk of infection. From this study also resulted a practical protocol 
(with an introduction on its rational) for the follow-up of immune-mediated diseases treated 
patients whose propose is to avoid infections that can result in treatment interruptions and 
worsening of the medical condition. 
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Resumo 
Introdução 
A interação entre agente infecioso e hospedeiro humano é complexa e está longe de 
estar completamente esclarecida, sendo expectável que ao longo do tempo venham a ser 
identificados novos aspetos. As terapêuticas biológicas prescritas no tratamento de doenças 
inflamatórias imuno-mediadas, isoladamente e/ou em associação ou na sequência de 
tratamento com imunomoduladores, mudaram a perspetiva de abordar estas patologias e 
trouxeram um novo paradigma ao seu tratamento. Em oposição aos fármacos mais antigos, os 
corticosteroides e os imunomoduladores, tais como metotrexato e inibidores das tiopurinas, 
as terapêuticas biológicas atuam em pontos específicos e restritos do sistema imune e, por 
isso, respostas imunológicas não esperadas podem surgir. As fontes de maior preocupação 
relativamente a estas novas terapêuticas são a possibilidade de indução de auto-imunidade, 
doenças neoplásicas e infeções. Nos doentes sob tratamento biológico, a infeção comporta-se 
de forma diferente relativamente a hospedeiros não imunossuprimidos, assumindo por vezes 
formas inesperadas. Além disso, dado que estas terapêuticas diminuem ou suprimem a 
resposta imune, o risco de infeção aumenta. O reconhecimento da associação entre as 
terapêuticas anti-fator de necrose tumoral alfa (anti-TNFα) e o desenvolvimento de 
tuberculose (TB), e entre a administração de natalizumab (um anticorpo monoclonal contra a 
adesão celular à molécula α4-integrina) e a ocorrência de leucoencefalopatia multifocal 
progressiva, constituíram marco importante na evidência do risco infecioso associado a estas 
novas terapêuticas. Contudo, continua a haver falhas nesse conhecimento sendo necessário 
aprofundá-lo e compreender melhor o comportamento da infeção no decurso da terapêutica 
biológica para aumentar a segurança dos doentes sob estas terapias. 
Entre os fármacos biológicos, os anti-TNFα têm permitido um largo campo de estudo 
por serem prescritos desde 1998, no tratamento de diversas patologias imuno-mediadas. As 
doenças granulomatosas e intracelulares são uma preocupação particular no tratamento com 
estes fármacos pois a capacidade de conter as infeções granulomatosas perde-se e a defesa 
contra agentes infeciosos intracelulares fica enfraquecida. Apesar do conhecimento já reunido, 
diversos aspetos necessitam de mais investigação, tais como: (i) como é que a TB se comporta 
em doentes tratados com anti-TNFα em termos de manifestações clínicas, diagnóstico e 
resposta à terapêutica e quão diferente é esse comportamento do que ocorre em hospedeiros 
não imunodeprimidos? (ii) num país como Portugal com uma incidência intermédia de TB 
justifica-se fazer de forma diferente o seu rastreio nos doentes antes de iniciar a terapêutica e 
durante a terapêutica biológica comparativamente aos países com baixa ou muito baixa 
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incidência de TB? (iii) quais são os melhores testes para o diagnóstico de TB latente de modo a 
evitar resultados “falsos”negativos? (iv) deveremos, durante a terapêutica com anti-TNFα e 
outras terapêuticas biológicas que tenham risco acrescido de reativação da infeção por 
Mycobacterium tuberculosis, rastrear para TB e, em caso afirmativo, como e com quê? (v) 
como podemos diminuir eficazmente o risco infecioso associado a estas terapêuticas 
imunomoduladoras e biológicas? 
 
Objetivos e Métodos 
Considerando as lacunas de conhecimento e as necessidades clínicas, o trabalho da 
presente Tese teve quatro objetivos principais: o primeiro foi a investigação de TB nas 
vertentes da prevenção e doença ativa em doentes sob anti-TNFα; o segundo e o terceiro 
foram o estudo de outras doenças graves granulomatosas e de doenças causadas por agentes 
infeciosos intracelulares em doentes tratados com anti-TNFα e/ou imunomoduladores, 
nomeadamente listeriose invasiva, nocardiose e infeções herpéticas disseminadas. O quarto 
objetivo focou-se na prevenção de infeção em doentes tratados com imunomoduladores e 
biológicos e formas de reduzir o risco de infeção, tendo sido desenvolvido um protocolo 
prático para rastreio e imunização, baseado em recomendações de diferentes autores e 
adaptado a esta população de doentes. 
A população estudada foi a dos doentes adultos com doença inflamatória imuno-
mediada seguida no Centro Hospitalar S. João, Porto, Portugal nos últimos 16 anos. Métodos 
retrospetivos, prospetivos e descritivos foram utilizados neste estudo. O critério de diagnóstico 
no que concerne aos testes de diagnóstico de TB latente foi baseado na positividade do TST 
e/ou dum teste IGRA específico para M. tuberculosis. 
Para atingir o primeiro objetivo foram avaliadas primeiro a TB ativa numa população 
de doentes portugueses com doença inflamatória imuno-mediada sob anti-TNFα e depois a 
segurança de reintrodução do anti-TNFα após tratamento de TB. Posteriormente o foco de 
estudo foi a TB latente e dois estudos prospetivos foram efetuados. No primeiro a 
sensibilidade e especificidade do TST comparada com com a dos testes IGRA´s (T-SPOT.TB e 
QFT-GIT) antes ou na troca de anti-TNFα foi estudada em doentes com doença inflamatória 
intestinal (DII). No outro estudo foi efetuado o rastreio seriado de TB latente em doentes sob 
anti-TNFα ao longo de 26 meses. 
Relativamente ao segundo objetivo, na cohort de doentes com DII tratados com anti-
TNFα e/ou imunomoduladores, foram revistos dois casos de listeriose invasiva, a que se seguiu 
revisão da literatura. Dois outros casos de um isolamento nas fezes, repetido e paradoxal, de 
Nocardia nova em doentes sob imunomoduladores com doença inflamatória intestinal foram 
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estudados e foi efetuada uma revisão da literatura sobre infeção por Nocardia spp. em 
doentes sob  imunomoduladores e/ou biológicos.  
Quanto ao terceiro objetivo, foram estudados um caso de infeção herpética cutânea e 
disseminada e um caso de varicela grave ambos em doentes sob imunomoduladores 
associados respetivamente a corticoide e a anti anti-TNFα, tendo sido feita uma revisão da 
literatura sobre estas doenças em doentes sob imunomoduladores e ou biológicos.  
 O quarto objetivo foi atingido através do desenvolvimento de normas práticas de 
prevenção de infeção em doentes com doença inflamatória imuno-mediada. Estas normas 
foram fundamentadas de acordo com recomendações de vários autores e adaptadas à 
população estudada.  
 
Resultados 
O estudo que focou a TB ativa reviu 25 casos de TB, diagnosticados de entre os 765 
doentes tratados com anti-TNFα entre 2001-2012, o que reflete uma incidência estimada de 
TB por 100,000 doentes/ano de prescrição de anti-TNFα de 1337, 792 e 405 para os doentes 
tratados com infliximab, adalimumab e etanercept, respetivamente. Sessenta por cento desses 
25 doentes apresentaram TB com envolvimento extra-pulmonar. Antes da prescrição de anti-
TNFα, 17 dos 25 doentes fizeram rastreio de TB latente, tendo quatro rastreio positivo, três 
dos quais fizeram tratamento com isoniazida. Em relação a uma população controle da 
comunidade da região do Porto com diagnóstico de TB ativa, emparelhada por sexo, idade e 
data de diagnóstico, os doentes tratados com anti-TNFα estudados apresentaram maior 
incidência de tuberculose extra-pulmonar e de febre na apresentação, e uma menor 
frequência de resultados positivos nos exames microbiológicos diretos. No entanto, o 
resultado não foi pior do que o da população controlo. 
Posteriormente e relativamente à TB associada a anti-TNFα, a retoma do fármaco após 
(ou durante) a terapêutica foi verificada em oito dos 28 doentes com diagnóstico de TB: cinco 
retomaram esta terapêutica depois de tratada a TB e três ainda durante o tratamento. Com 
uma mediana de seguimento de mais de 2,5 anos não se verificou em nenhum doente 
recorrência de TB. 
Relativamente à prevenção de TB, o rastreio prospetivo efetuado em 250 doentes com 
DII antes do início ou em troca de anti-TNFα, permitiu o diagnóstico de TB latente em 29% 
deles. Genericamente, a sensibilidade da prova de tuberculina foi mais elevada (81% versus 
35%) assim como o valor preditivo negativo (93% versus 80%, respetivamente) quando 
comparado com o teste QFT-GIT, independentemente da presença e do tipo de terapêutica 
imunossupressora. A concordância entre estes dois tipos de testes foi baixa.  
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Num outro estudo que englobou 46 doentes com DII sob infliximab, após rastreio 
negativo de TB prévio ao infliximab, foi efetuado o rastreio seriado de TB seis vezes ao longo 
dos 26 meses, tendo sido utilizados os testes T-SPOT.TB, tuberculina e em três dos rastreios 
também o QFT-GIT. Dezasseis (29%) dos doentes tiveram pelo menos um dos três testes 
positivo ao longo dos 26 meses. O TST teve a maior sensibilidade, seguido do T-SPOT.TB. 
Doentes do sexo masculino e com longa duração da DII converteram mais frequentemente 
estes testes, cujos resultados foram muito pouco concordantes entre eles; os testes IGRA 
positivos não se reproduziram nos rastreios subsequentes e tiveram valores muito próximo do 
limite da positividade. Dos 16 doentes com diagnóstico de TB latente, 15 foram tratados com 
isoniazida; não se verificou nenhum caso de doença tuberculosa.  
Relativamente a outras doenças granulomatosas, diagnosticaram-se e trataram-se dois 
casos de listeriose invasiva (meningite) em doentes com o diagnóstico de colite ulcerosa 
tratados com infliximab, tendo um deles infeção pelo vírus da imunodeficiência humana. 
Ambos tiveram evolução favorável sem sequelas e um deles retomou infliximab. 
Em dois doentes tratados com azatioprina e pulsos de corticosteroides por DII, uma Nocardia 
usualmente patogénica, Nocardia nova, foi isolada em subsequentes amostras de fezes, sem 
sintomatologia associada. Foi excluída doença cutânea e invasiva. Um destes doentes foi 
tratado com cotrimoxazol nos três primeiros meses após ter iniciado anti-TNFα. A preocupação 
foi a de que a colonização pudesse disseminar e causar doença sob terapêutica mais 
imunossupressora. A situação clínica foi seguida e foi efetuada uma revisão da literatura 
relativa a nocardiose em doentes sob imunomoduladores/biológicos. 
Relativamente à infeção por vírus do grupo herpes sob imunomoduladores/biológicos, 
uma forma grave de Herpes simplex cutâneo disseminado foi diagnosticada numa jovem com 
doença de Crohn tratada com corticoide e azatioprina, cuja evolução clínica foi favorável sob 
tratamento com aciclovir endovenoso.  
Uma forma grave de varicela num jovem com doença de Crohn tratado com infliximab e 
azatioprina foi também estudada, tendo sido necessária ventilação invasiva e suporte 
inotrópico. A evolução foi favorável não sendo detetadas sequelas e foi retomado o anti-TNFα 
com sucesso. Em ambas as situações foram efetuadas revisões da literatura destas doenças 
sob imunossupressão. 
No que se refere ao quarto objetivo, foi desenvolvido um protocolo de fácil utilização 
relativo a rastreio, prevenção de infeção (incluindo imunizações) e aconselhamento em 
doentes que vão iniciar imunomoduladores ou biológicos devido a doença auto inflamatória, 
que foi testado nesta cohort, 
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Conclusões 
Na interseção entre terapêutica anti-TNFα (só ou em associação com 
imunomoduladores) e infeção, a TB foi a principal preocupação na amostra de doentes adultos 
estudados, sendo as formas extrapulmonares e disseminadas muito mais comuns do que na 
população em geral, ainda que o resultado não tenha sido pior. A reintrodução de terapêutica 
com anti-TNFα depois da TB revelou-se segura. Relativamente ao rastreio de TB antes da 
medicação com anti-TNFα, a prova de tuberculina permanece importante já que mostrou 
maior sensibilidade quando comparada com os testes IGRA mesmo em doentes sob 
terapêuticas imunossupressoras. No rastreio de TB durante a prescrição de anti-TNFα, que tem 
sido alvo de muitas mais dúvidas, os nossos resultados mostraram também maior sensibilidade 
da prova de tuberculina do que os testes IGRA, e a frequente conversão e reversão dos 
resultados destes últimos, com valores próximos do limiar da positividade. Assim, sugere-se a 
manutenção da prova da tuberculina no rastreio da TB enquanto não existirem testes 
melhores e, no rastreio durante a prescrição de anti-TNFα, que o mesmo seja feito nos 
primeiros anos da prescrição e sempre de uma forma personalizada de acordo com o risco 
percetível de TB.  
Conforme indicado pelos nossos resultados em concordância com o referido na 
literatura, existe também risco de outras infeções graves granulomatosas e intracelulares, 
associadas à prescrição de anti-TNFα e/ou imunomoduladores. Não estando ainda 
estabelecido o risco de infeção em doentes medicados com as terapêuticas biológicas mais 
recentes, a vigilância clínica nestes casos é de importância acrescida.  
Atendendo ao risco real de infeção verificado também nesta cohort, o 
aconselhamento, rastreio e profilaxia, incluindo imunização preferencialmente antes dos 
imunomoduladores e biológicos são medidas importantes na redução do risco de infeção. 
Deste estudo resultou um protocolo prático cujo propósito é evitar infeções que possam 
resultar em interrupção da terapêutica biológica e imunomoduladora e agravamento da 
condição médica. 
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1. Thesis outline 
The present PhD thesis is based on several different studies, which are organized and detailed 
in nine chapters. 
 
Chapter 2 presents an introduction on immunomodulation and risk of infection, concerning 
different therapies and risk evaluation. 
 
Chapter 3 resumes the aim and specific objectives of this thesis. 
 
Chapters 4, 5, 6 and 7 present the main results of the different studies developed to achieve 
the four main objectives of the thesis. 
 
Chapter 4 presents original cohort studies related to TB: first the cases of active TB in patients 
under anti-TNFα because of several immune-mediated diseases, then the re-institution of anti-
TNFα after TB. At last the prospective screening of latent TB: before anti-TNFα or on the switch 
of anti-TNFα and then during infliximab therapy.  
 
Chapter 5 presents original case studies in patients with other granulomatous infection 
(invasive Listeriosis, Nocardiosis) and a literature review. 
 
Chapter 6 presents original cases study of intracellular herpes virus infection (severe varicella 
and disseminated cutaneous herpes simplex infection) and a literature review. 
 
Chapter 7 presents a proposed protocol for counselling, screening, and prophylaxis including 
immunization, before prescription of common immunomodulators and biological therapies. 
 
Chapter 8 includes a brief general discussion of the work and some recommendations based 
on our results. 
 
Chapter 9 depicts some final remarks. 
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2.  Rationale 
2.1. Infection 
 
Infection remains in humankind from ancestral times. However, just recently, due to 
advances in medical science and technology, namely due to the use of antimicrobials and 
vaccines, was possible to protect the human population from important infectious agents. 
Several potential severe infections like measles, poliomyelitis, tetanus, diphtheria, to speak 
only a few are now controlled in developed countries.  The increase in life expectancy during 
the 20th century was largely due to reductions in infectious disease mortality in consequence 
of immunization and improvements in child survival1. However, infectious diseases remain a 
major cause of illness, disability and death. Remarkable, concerns about infection changed 
across times. Recently, globalization enabled the likelihood of infectious diseases to occur and 
spread rapidly across the planet. 
In the eighties of the XX century, the human immunodeficiency virus (HIV) infection 
become a challenge in infectious diseases, and a model to understand the implications of a 
virus that attacks directly the immune system that is crucial for the protection against 
infection. Diagnosing and treating the opportunistic infections in HIV infected persons that 
occur in consequence of immune depression has been a singular and huge experience.   The 
research and workup enabled what at first was just a mirage: the reconstitution of immunity 
by the suppression of the viral load and rise of TCD4 lymphocytes count. A new era in HIV 
history was accomplished. Yet, no cure is available despite the huge progress made. 
Although other conditions are relevant in the field of infection - old and very old 
persons, immunosuppressed patients due to severe medical conditions and treatments, 
haematological or solid organ transplanted receptors - are on the rise and have an increased 
risk of infection2-5. The crosstalk between the human host and the infectious agent is far from 
being completely understood as it has several types of response and the immune pathways 
involved are complex. Furthermore, new challenges arrived with the use of biological therapy 
and immunomodulators for the treatment of inflammatory immune-mediated diseases. 
 
 
  
  
INFECTION AND IMMUNOMODULATION 
 
5 
2.2. Inflammatory Immuno-mediated Diseases  
 
For several reasons, some of them unknown, the increase of inflammatory immune-
mediated acquired disorders observed, particularly of inflammatory bowel diseases (IBD), in 
the newly industrialised countries is significant6-9. Genetic and environmental factors, and 
innate immunity are involved in the genesis of these diseases10. The “hygiene hypothesis” 
suggests that the decline in infectious diseases due to better hygiene may have contributed to 
the increase of immune-mediated diseases11. In patients with such diseases the capacity of 
self-tolerance is lost12. These diseases themselves increase the susceptibility to infection, 
especially among patients with the most active ongoing inflammatory disease activity10.  
The development of therapies to treat such disorders by inducing self-tolerance 
started 60 years ago, and has been particularly remarkable in the last decades.  Since then, the 
therapeutic approach has been largely the treatment with steroids, immunomodulators and 
more recently also biological drugs that modulate the immune system answer. The goal of 
immunomodulation in the treatment of immune-mediated diseases is to produce self-
tolerance, without a severe immunosuppression that may put the patient at increased risk of 
malignancies and infection12. The main current challenge of this therapeutic approach is that 
such pharmacological action often interferes with the immune system in varied and sometimes 
unexpected ways.  
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2.2.1. Therapies of inflammatory immunomediated diseases and risk of 
infection 
 
Early therapeutic agents, like glucocorticoids and thiopurines, lack specificity13. Broad 
suppression of immune cell function and replication caused by these agents frequently also 
induce toxicity and other adverse effects, including infections. Glucocorticoids for instance 
decrease the number of circulating lymphocytes and eosinophils; macrophages and monocytes 
reduce the production of inflammatory cytokines when steroids are administered and adverse  
metabolic and endocrine effects are to be expected, especially in patients under prolonged 
and high dose treatment13. Glucocorticoids therapies are associated with infections caused by 
bacteria, micobacteria, virus and parasites14,15.  
Immunomodulators like anti proliferative agents such as methotrexate (T cell inhibitor 
of folate metabolism), leflunomide (inhibitor of T and B cell purine synthesis) and azathioprine 
(inhibitor of purine nucleic acid metabolism) have also anti-inflammatory actions with 
potential adverse effects and risk of infections, namely those dependent on T cell immunity as 
those caused by the herpes virus group and  Pneumocystis jiroveci16.  
More recently, biologic therapeutic agents were developed. They are proteins with 
human or human/murine constructs that are directed against cells from the inflammatory 
process or against inflammatory cytokine activity17. They target particular receptors of the 
immune response and changed the paradigm of treatment, owing to its good efficacy and 
better safety profiles10,13,18,19. The targets of these biological therapies are cytokines, B cells, 
and co-stimulation molecules18. Anti-cytokines include anti-TNFα, anti-interleukin (IL) 1, anti-IL 
6 anti-IL 12, anti-IL 17 and anti-IL 23 molecules. B-cell depletion drugs include anti-CD20 
antibodies agents and B cell receptor (BCR) modulation by the B-lymphocyte stimulator 
(BLyS)18. More than 45 antibodies are now marketed for therapy (including in oncology) or 
imaging in western countries. Nowadays a focus on early treatment with biological therapies is 
recommended, although none is yet available as first-line medication for autoimmune 
diseases18.  
A sharp rise on the development of biological agents for the treatment of immune-
mediated inflammatory diseases is expected for the next years and side effects, including the 
risk of infections, are partially unknown contrary to older immunomodulatory therapies. The 
challenge remains to selectively interfere with immune responses that causes autoimmunity 
while keeping an intact response to infectious agents, and this is difficult to reach20.  
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Some of the biologic therapies have been useful in several immunomediated diseases while 
others are specific for a few or a single disease. Anti-TNFα monoclonal antibodies, for instance, 
are effective in the treatment of various inflammatory diseases, such as IBD, rheumatoid 
arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA). Infliximab, adalimumab, 
and golimumab are monoclonal antibodies directed against TNF-α, etanercept is a soluble 
receptor for TNF-α and certolizumab pegol is a pegylated fragment of a humanized anti-TNFα 
monoclonal antibody19. Several years of knowledge and prescription makes anti-TNFα a 
reference in biologic therapies. Infliximab was the first anti-TNF α to be approved (1998) for 
the treatment of IBD and RA, and a large clinical experience of its use already exists. Being 
TNFα fundamental for activation of macrophage and phagosome, differentiation of monocytes 
into macrophages and recruitment of neutrophils and macrophages, granuloma formation and 
its maintenance and clearance of intracellular pathogen, anti-TNF α drugs increase  
considerably the risk of granulomatous, namely TB,  and intracellular infections in patients 
under these therapies21. TB was really the first infectious of high concern associated with 
biological therapy22.  
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2.2.2. Tuberculosis 
 
Tuberculosis was first associated to anti-TNFα therapy in 200122, about three years 
after infliximab approval for treating IBD and RA patients. In general, the TB occurring in 
patients under anti-TNFα therapy results mainly from reactivation, frequently is extra-
pulmonary and disseminated, progresses more rapid than in other patients and has less 
granuloma formation23,24. The risk of TB occurrence is not the same for different anti-TNFα 
therapies25 and is also dependent on the local TB incidence. The standard performance of TB 
screening and treatment before anti-TNF α (and also before leflonamide, teriflunomide, 
ustekinumab and alemtuzumab administration) is considered to reduce the risk of the disease 
by 80%26. Although, it should be taken into consideration that the most part of the studies 
concerning patients treated with anti-TNF α are from western countries with high income that 
have a low or very low incidence of TB. Thus, more studies are needed, especially in countries 
with intermediate TB incidence like Portugal, or higher TB incidence, as the risk may be higher. 
Considering the risk of TB associated with the therapy anti-TNF α and the intermediate or high 
TB incidence in such countries, several questions arise, such as:  (i) how should the TB 
screening proceed under anti-TNF α therapy?  (ii) should the rescreening be done only in 
patients at higher risk of TB? (iii) how frequently should the rescreening be done (e.g. 6 
months, annual)? (iv) which are the most efficacious tests for both screening and rescreening 
(i.e., tuberculin or specific IGRA’s tests)? (v) what about the cut-off for tests positivity? These 
last questions are pertinent especially because under immunosuppressive therapy, the TST 
may be less often positive and, due to the reduction of interferon gamma produced by the 
lymphocytes, QFT-GIT and T-SPOT.TB may be also less often positive27,28. In short we still miss 
better tests for a correct diagnosis of latent TB. 
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2.2.3. Other granulomatous and intracellular infections 
 
In addition to TB, other intracellular and granulomatous infections, such as those 
caused by Listeria monocytogenes, Legionella pneumophila and Nocardia, several fungal 
infections (aspergilosis, candidosis, cryptosporidiosis) and the more rare endemic mycosis 
(histoplasmosis, coccidioidomycosis), are associated with anti-TNFα therapy21,29.  
Intracellular DNA virus infection and biological or immunomodulatory therapy 
reactivation of Herpes virus family agents, in particular Herpes simplex, are a frequent concern 
in patients under anti-TNFα treatment. In fact, a significantly increase of Herpes simplex 
reactivation in such patients with inflammatory rheumatic diseases was found by some 
authors30,31. Outside of anti-TNFα therapies, fingolimod that prevents lymphocyte egress from 
lymphoid tissues, and alemtuzumab, an anti CD52 drug, were both  associated with herpes 
virus infections32, as well as tofacitinib, an oral Janus Kinase (JAK) 1/3 inhibitor used for the 
treatment of rheumatoid arthritis31,33, IBD and psoriasis34. Concerning alemtuzumab, for the 
treatment of multiple sclerosis, there is even the recommendation of treatment with acyclovir 
at least on the first month after infusion35.  
Considering that age is a relevant risk for the development of varicela zoster virus 
reactivation, for those older adults treated with biological therapies herpes zoster is a concern.  
Another concern is the risk of hepatitis B virus reactivation under anti-TNFα 
therapies36,37.  This reactivation may result in fulminant liver failure and death38,39. Although 
the greatest risk concerning this intracellular DNA virus reactivation is rituximab and other anti 
CD20 therapies that cause depletion of B-cells.  
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2.2.4. The complexity and hidden faces of this risk of infection  
 
Age, the presence of comorbidities, such as diabetes mellitus, chronic kidney disease 
or impaired lung function and concomitant glucocorticoid prescription or a previous serious 
infection are considered factors that increase the risk of serious infection across many studies 
in patients treated with immunomodulators and or biologics3,5. The dose of the therapeutic 
biological agent, the disease to be treated, past immunosuppression or concomitant therapy 
are to be considered in risk evaluation2,40,41.  For instance, in RA patients treated with 
tocilizumab (anti-IL6), when rituximab was previously prescribed a greater risk of mild and 
moderate infections was found42. Demography issues and asymmetries in risk of infectious 
diseases distribution are important concerning, for instance, TB and endemic mycosis43,44. Also, 
lymphopenia associated with immunomodulators or biologics, whenever is severe and 
prolonged, may constitute a risk for infection. For instance, alemtuzumab for the treatment of 
B cell chronic lymphocytic leukaemia may be associated with low CD4+ and CD8+ lymphocyte 
counts that may not return to baseline values for more than one year, being preconized 
monitoring cytomegalovirus (CMV) infection and prescribe prophylactic medication against 
Pneumocystis jiroveci and Herpes virus infection 
(http://www.campath.com/hcp/AboutCampath.html). Also lymphopenia associated with the 
prescription of dimethyl fumarate should be considered a risk for PML45.  
In real life, patients with inflammatory immunomodulated diseases get concomitant 
(or past) prescription of immunomodulators and glucocorticoids and thus the risk of biological 
monotherapy is hard to extrapolate. Concerning the risk of infection associated with these 
therapies, there is a need to know if any increase in risk of infection is constant over time, or 
whether there are times when the risk is higher or lower and define an at-risk window;  that is, 
the period when adverse events should be attributed to a drug46. And of course in these 
studies our main focus was severe infections: those requiring hospitalization, if outpatient at 
onset, or those in the need of intravenous treatment.  
Concerning the infection risk over time, there are studies where this risk was greatest 
during the initial 6 months of treatment and then decreased over time47, suggesting positive 
correlation between infection and the systemic inflammatory burden of the underlying 
disease. Such correlation may explain why severe infections tended to be higher in patients 
with RA and IBD than in patients with psoriasis or AS41. 
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Large national and international registers may reveal some of the patterns of rare 
adverse events that might otherwise be hidden. The overall incidence of severe infections in 
patients treated with anti-TNFα has been reported from large numbers of treated patients for 
several autoimmune diseases. For instance, concerning RA in European patients treated with 
anti-TNFα and anakinra, an anti-IL-1 therapy, the incidence of serious infection  was 2.7-2.8 
times higher in patients receiving biologics than in those treated with conventional disease-
modifying anti rheumatic drugs (DMARDs)48. In another meta-analysis including 42,330 
patients with RA from 106 randomized trials, a standard or higher dose of biological drugs 
(pooled analysis of etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, 
anakinra, tocilizumab, abatacept, and rituximab) was associated with an increase of serious 
infections compared with the use of traditional DMARDs in patients with RA. Although, this 
association was not evident under low-dose biological drug treatment40. Moreover, in another 
meta-analysis of 44 randomized controlled trials involving 11,700 patients treated with  anti-
TNFα and 5,901 subjects receiving placebo or traditional DMARDs, patients with RA receiving 
anti-TNFα monoclonal antibodies (mAbs) other than etanercept (adalimumab, certolizumab 
pegol, and infliximab) had a higher risk of serious infection than those receiving placebo or 
traditional DMARDs49.  
Nevertheless other studies concerning the use of biologic agents didn’t result in 
increased risk of infection50-52. The same was reported from four large US administrative 
databases (the Safety Assessment of Biologic Therapy project), where anti-TNFα use was not 
more commonly associated with hospitalization than use of DMARDs in patients with various 
autoimmune disease, such as RA, AS, IBD, and psoriasis52.  
 
Another issue is the risk of infection among different anti-TNFα treatments: - infliximab 
and adalimumab (mAbs) - compared with etanercept: from a Dutch53 and Italian54 registry 
mAbs were associated with a higher infection rate than etanercept, but not in a British 
registry47.  
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2.2.5. Infectious risk mitigation strategies: counselling, prophylaxis and 
immunization 
Due to the infectious risk associated to biologics, immunomodulators and steroids, 
mitigation strategies are welcome.  
Granulomatous and intracellular infections are of concern, especially when anti-TNFα 
drugs are prescribed. TB is a key issue in prevention; concerning other granulomatous 
infections transmitted from food or water and spread in hot tubs, counselling according to the 
risk is important. The risk of herpes reactivation deserves prophylaxis in some situations. 
Prophylaxis for Pneumocystis jiroveci is needed in patients treated with some 
immunomodulators especially when in association.  
Finally immunizations, indications and contraindications, have to be considered as 
strategies to mitigate the infectious risk and to keep safety on biological therapy.  
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3. Objectives 
 
This thesis had four main goals: 
 
Goal 1: 
Tuberculosis: from the disease to latent tuberculosis screening (Chapter 4) 
The first aim of this thesis was to summarize the evidence regarding TB in Portuguese patients 
treated with anti-TNFα therapies. First, patients with active disease were reviewed, and then 
the safety of the reintroduction of anti-TNFα therapy after a TB diagnosis was evaluated. 
Concerning latent TB screening, the prospective screening before anti-TNFα or on the switch of 
anti-TNF therapy was done, as well as the screening in patients during infliximab therapy. 
 
 
Goal 2: 
 Other severe granulomatous infections (Chapter 5)  
The second aim of this thesis was to identify other severe granulomatous infections and to do 
a literature review on the subject. 
 
Goal 3:  
Severe intracellular DNA herpes virus infections (Chapter 6) 
The third aim of this thesis was to summarize severe herpes virus infections and to do a 
literature review. 
 
 
Goal 4:   
Infectious prevention (Chapter 7) 
The fourth aim of this thesis was to develop a practical approach to screening, monitoring and 
prophylaxis on patients about to start biologics, based on the risks identified on goal 1, 2 and 
3.  
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4. Tuberculosis: from the disease to latent tuberculosis screening 
 
As previously indicated, the first aim of this thesis was to summarize TB in Portuguese 
patients treated with anti-TNFα therapies. To reach this goal, first 25 cases of active disease 
from a population of 765 treated patients were reviewed. Then, the reintroduction of anti-TNF 
α therapy after TB diagnosis was followed.   
The incidence of TB per 100,000 patient-years was estimated to be 1337, 792 and 405 
for those on infliximab, adalimumab and etanercept therapy, respectively, and 60% of the 
cases were extra-pulmonary forms of TB.  
From the 28 patients with TB associated with anti-TNF α drugs (25 published in 2013) 
eight of them restarted anti-TNF α therapy, three of them even during TB treatment, and no 
recurrence of TB was observed. 
 
 
Two studies were conducted: 
 
4.1. Tuberculosis in anti-TNF α treated patients remains a problem in countries with 
intermediate incidence: analysis of 25 patients matched with a control population 
Journal of Crohn's & colitis 2013; 7:e 486-492.  
Abreu C*, Magro F*, Santos-Antunes J, Pilão A, Rodrigues-Pinto E, Bernardes J, 
Bernardo A, Magina S, Vilas-Boas F, Lopes S, Macedo G, Sarmento A. 
*These authors contributed equally in the design, conception, analysis and paper writing 
 
 
4.2 Reintroduction of anti-TNF α  therapy after (or even during) anti-TNF α  associated 
tuberculosis in immune-mediated diseases 
Journal of Crohn's & colitis 2016; 10:120-121. 
Abreu C, Sarmento A, Magro F.  
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The following work was about latent TB in IBD patients: in the first study a prospective 
screening of latent TB (being the diagnosis based on a positive TST or/and QFT-GIT test in the 
absence of active disease) in 250 patients about to start or switch from anti-TNF α therapy was 
done. In the second study a prospective screening involved 46 patients treated with infliximab 
along 26 months. The diagnosis of latent TB was based on positivity of TST, TB.SPOT.TB and/or 
QFT-GIT tests that were applied six times across the study. 
In the first study, 72 (29%) patients had a diagnosis of latent TB. When compared the 
performance of TST and QFT-GIT tests, TST had an overall higher sensitivity (81% versus 35%) 
and a higher Negative Predictive Value (93% versus 80%) irrespective of the presence and kind 
of backbone immunosuppressive therapy. 
On the second study 16 from 46 patients convert at least one TB test during the follow-
up of 26 months and again the TST had a higher sensitivity than the IGRA’s tests; 15 of them 
were treated with isoniazid and none had a diagnosis of active TB. 
Two additional studies were conducted: 
 
 
4.3 The tuberculin skin test still matters for the screening of latent tuberculosis 
infections among inflammatory bowel disease patients. 
Digestive and  Liver Diseases 2016; 48: 1438-1443 
Abreu C, Almeida F, Ferraz R, Dias CC, Sarmento A, Magro F. 
 
 
4.4 Serial tuberculosis screening in inflammatory bowel disease patients under anti-
TNF alpha therapy 
Journal of Crohn's & colitis 2017 – accepted, in press; 
Abreu C, Afonso J, Dias CC, Ruas R, Sarmento A, Magro F. 
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4.1 Tuberculosis in anti-TNF α treated patients remains a problem in countries with 
intermediate incidence: analysis of 25 patients matched with a control population 
 
  Journal of Crohn's & colitis 2013; 7: e 486-492.  
Abreu C*, Magro F*, Santos-Antunes J, Pilão A, Rodrigues-Pinto E, Bernardes J, Bernardo 
A, Magina S, Vilas-Boas F, Lopes S, Macedo G, Sarmento A. 
*These authors contributed equally in the design, conception, analysis and paper writing 
 
 
  
  
INFECTION AND IMMUNOMODULATION 
 
19 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
  
  
INFECTION AND IMMUNOMODULATION 
 
20 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
 
  
INFECTION AND IMMUNOMODULATION 
 
21 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
 
 
  
  
INFECTION AND IMMUNOMODULATION 
 
22 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
 
  
INFECTION AND IMMUNOMODULATION 
 
23 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
 
 
  
  
INFECTION AND IMMUNOMODULATION 
 
24 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
 
 
  
  
INFECTION AND IMMUNOMODULATION 
 
25 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
 
 
  
  
INFECTION AND IMMUNOMODULATION 
 
26 
 
 
4. Tuberculosis: from the disease to the screening of latent tuberculosis 
 
 
 
 
 
4.2 Reintroduction of anti-TNF α therapy after (or even during) anti-TNF α associated 
tuberculosis in immune-mediated diseases 
Journal of Crohn's & colitis 2016; 10:120-121. 
 Abreu C, Sarmento A, Magro F. 
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4.3  The tuberculin skin test still matters for the screening of latent tuberculosis infections 
among inflammatory bowel disease patients. 
Digestive and  Liver Diseases 2016; 48:1438-1443 
Abreu C, Almeida F, Ferraz R, Dias CC, Sarmento A, Magro F. 
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4.4  Serial tuberculosis screening in inflammatory bowel disease patients under anti-TNF 
alpha therapy 
Journal of Crohn's & colitis 2017 – in press; 
Abreu C, Afonso J, Dias CC, Ruas R, Sarmento A, Magro F. 
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5. Other severe granulomatous infections 
 
The second aim of this thesis was to identify other granulomatous infections in 
patients treated with biologics, its behaviour and the outcome, and to perform a literature 
review on the topic. 
We herein present two cases of invasive listeriosis, with meningitis, in two adults (51 
and 69 years-old) suffering from ulcerative colitis and treated with infliximab plus steroids. 
One was HIV 1 infected. Both presented as an acute disease and were empirically treated since 
the admission, being the outcome good. The HIV infected patient reassumed infliximab and he 
is doing well with a follow-up period of six years. A total of 43 cases of invasive listeriosis 
associated with anti-TNFα were reported in the literature: 23 had rheumatoid arthritis, 14 
Crohn’s disease, three psoriatic arthritis, one ulcerative colitis and one Still’s disease; 15 died. 
Isolation of a pathogenic Nocardia, Nocardia nova, in stool was not, to our knowledge, 
documented before in patients with immune-mediated diseases. We found two patients with 
a persistent isolation of the bacteria, without invasive disease. Concerns due to the risk of 
dissemination under biological therapies drive the article that follows about Nocardiosis 
among immunomodulated inflammatory bowel diseases patients. Ten cases of invasive 
nocardiosis among IBD patients are published, seven of them were doing anti-TNFα.  
 
Three studies were conducted:  
 
5.1 Listeria infection in patients on anti-TNF treatment: report of two cases and review 
of the literature.  
Journal of Crohn's & colitis 2013; 7(2):175-182.  
Abreu C, Magro F, Vilas-Boas F, Lopes S, Macedo G, Sarmento A. 
 
 
5.2 Stool isolation of Nocardia nova in two immunomodulated patients with 
inflammatory bowel diseases. 
Journal of  Clinical Gastroenterology 2016; 50(1):92.  
Abreu C, Carvalho T, Sarmento A, Magro F. 
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5.3  Nocardia infections among immunomodulated inflammatory bowel disease 
patients: a review. 
World Journal of Gastroenterology 2015; 21(21):6491-6498. 
Abreu C, Rocha-Pereira N, Sarmento A, Magro F. 
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5.1 Listeria infection in patients on anti-TNF treatment: report of two cases and review   
of the literature.  
Journal of Crohn's & colitis. 2013; 7(2):175-182.  
Abreu C, Magro F, Vilas-Boas F, Lopes S, Macedo G, Sarmento A. 
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5.2  Stool Isolation of Nocardia nova in two immunomodulated patients with    
inflammatory bowel diseases. 
Journal of Clinical Gastroenterology 2016; 50(1):92.  
Abreu C, Carvalho T, Sarmento A, Magro F. 
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5.3 Nocardia infections among immunomodulated inflammatory bowel disease patients: a 
review. 
World Journal of Gastroenterology 2015; 21(21):6491-6498. 
Abreu C, Rocha-Pereira N, Sarmento A, Magro F. 
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6. Severe intracellular DNA Herpes virus infections 
 
 
The third aim of this thesis concerned severe Herpes virus infections among patients 
treated with immunomodulators, biologics or steroids.  
First we describe the case of a young lady treated with azathioprine and steroids for an 
ulcerative colitis who had a disseminated cutaneous herpes simplex virus infection resulting 
from a reactivation of HSV type1. She was successfully treated with intravenous acyclovir. In 
the literature, we found five cases of serious herpes simplex infection in IBD patients, all but 
one treated with steroids alone or in association with azathioprine; two of them died. 
Concerning varicella zoster virus (VZV), we describe a varicella pneumonia in a young 
male treated with azathioprine and infliximab for Crohn’s Disease. Because a severe adult 
respiratory distress syndrome developed, he needed inotropic support and mechanical 
ventilation for 11 days. He recovered and infliximab was re-started two months later. In the 
literature twenty cases of primary varicella infection have been reported in IBD patients and 
five of them died. 
 
Two studies were conducted: 
 
6.1 Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease 
under azathioprine and steroids: first case report and literature review.  
Journal of Crohn's & colitis 2014; 8(4):326-330.  
Santos-Antunes J*, Abreu C*, Magro F, Coelho R, Vilas-Boas F, Andrade P, Lopes S, 
Macedo G. 
 
*the first and second authors contributed equally in the design, conception, analysis and paper writing 
  
 
6.2 Varicella complicated by severe pneumonia and shock in an immunosuppressed 
Crohn's disease patient under azathioprine and anti-tumour necrosis factor alpha.  
Journal of Crohn's & colitis 2015; 9(12):1176-1178. 
Abreu C, Santos L, Magro F.  
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6.1 Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease 
under azathioprine and steroids: first case report and literature review.  
Journal of Crohn's & colitis. 2014; 8(4):326-330.  
Santos-Antunes J*, Abreu C*, Magro F, Coelho R, Vilas-Boas F, Andrade P, Lopes S, 
Macedo G. 
 *the first and second authors contributed equally in the design, conception, analysis and paper writing 
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6.2 Varicella complicated by severe pneumonia and shock in an immunosuppressed Crohn's 
disease patient under azathioprine and anti-tumour necrosis factor alpha.  
Journal of Crohn's & colitis 2015; 9(12):1176-1178. 
Abreu C, Santos L, Magro F.  
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7. Infectious prevention 
 
The fourth aim of this thesis was to develop a practical approach to screening, monitoring 
and prescription of immunizations and chemoprophylaxis on patients about to start biologics, 
based on the risks identified on goal 1, 2 and 3. The purpose is to reduce the infectious risk and 
raise the safety of these therapies. 
 
Two studies were conducted: 
 
7.1 Immunisations in Crohn's disease: who? why? what? when?  
Best Practice & Research of Clinical Gastroenterology 2014; 28(3):485-496. 
Magro F, Abreu C. 
 
 
7.2 Screening, prophylaxis and counselling before biological therapies: a practical 
approach 
Digestive and Liver Diseases, 2017 – in press accepted manuscript 
Abreu C, Sarmento A, Magro, F. 
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Best Practice & Research of Clinical Gastroenterology 2014; 28(3):485-496. 
Magro F, Abreu C.  
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7.2    Screening, prophylaxis and counselling before biological therapies: a practical approach 
Digestive and Liver Disease 2017 – in press accepted manuscript 
doi: 10.1016/j.dld.2017.09.002 
Abreu C, Sarmento A, Magro, F. 
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8. Discussion  
 
The focus of this Thesis was infection and risk of infection in Portuguese patients treated 
with anti-TNFα, alone or in association with immunomodulators and/or glucosteroids. 
Granulomatous and intracellular infections were the main concern.  
In the cohort studied, the incidence of tuberculosis per patients/year during therapy with 
infliximab, adalimumab or etanercept was very high, compared with other series. The severity 
of most of the cases, 60% of which being extra pulmonary, the interruption of anti-TNFα 
therapy and cases of immune reconstitution inflammatory syndrome (IRIS) associated with the 
withdrawal of anti-TNF´s were a big concern.  As active TB in the field of immunosuppression 
results generally from the reactivation of latent forms, the diagnosis and treatment of latent 
TB is crucial. Although, despite a more accurate diagnosis of latent TB on the last years, active 
TB is still diagnosed (data not showed).  
It is estimated that TB screening before anti-TNFα therapies reduces the risk of active TB in 
about 80-90% of the cases26,55. Two situations concur to this: patients may be new infected 
with TB or the diagnosis of latent TB may be a “false” negative result. The first part is hard to 
control and depends on the incidence of TB in the general population and the exposure to TB 
patients. The second one is the result of not having gold standard tests for the diagnosis of 
latent TB neither tests with high predictive value for progression to active TB.  In our study, TST 
was the test with higher sensitivity (compared with IGRA’s test) irrespective of concurrent or 
previous immunomodulator or biological therapy or before these treatments. Thus, despite 
the specificities of the cohort studied (BCG vaccinated at birth, living in an intermediate 
incidence area of TB and not including people younger than 18 years old), the results obtained 
are interesting especially considering the current opinion that IGRA’s tests should replace the 
oldest TST. Although both TST and IGRA’s represent indirect markers of 
M. tuberculosis exposure and indicate a cellular immune response to this pathogen, having 
both  low predictive value for progression to active TB 56Nowadays, a shortage of TST exists 
due to the increasing trend of its replacement by IGRA’s tests that are much more expensive 
and thus more appealing to the pharmacology industry. Of course TST has limitations: may 
have a positive result due to repeated BCG vaccination after the first year of life, has inter-
reader variability and, like in  IGRA’s, conversions and reversions are observed 57. 
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Another interesting finding of our study was that IGRA’s in patients already 
immunosuppressed despite having a higher specificity had also a lower sensitivity that can 
result in the sub-diagnosis of latent TB. Thus, in the absence of a test that can predict the risk 
of reactivating a latent TB, probably should be better to favour tests with higher sensitivity.  
The recommendations of the National Institute for Health and Care Excellence (NICE), 
concerning immunosuppressed patients, is that the optimal strategy for latent TB diagnosis is 
to offer an IGRA as a first-line test and then use TST (≥ 5 mm) as a second-line test in IGRA 
negative cases58.  
Concerning the screening for TB during treatment with anti-TNFα, this is even more 
difficult issue to solve and a lot of recommendations have been proposed59-64. In our cohort, 
despite the ongoing therapeutic immunosuppression TST became positive in 12 out of 46 
patients across 26 months.  Curiously, all but one TST conversion occurred on the first three 
screening tests, turning the boosting effect rather improbable.  In the same population, T-
SPOT.TB turned positive in 7 patients. The concordance between TST and IGRA positive results 
was fable. On the follow-up, IGRA tests reverted frequently, and QFT-GIT results, when 
positive, were close to the cut-off values. In fact, IGRA’s are highly dynamic in nature, with high 
rates of conversions and reversions when repeated tests are performed56. Concerning for 
instance serial testing of health care workers, TST seems preferable to the IGRAs due to  high 
rates of conversions and reversions of IGRA’s which are harder to interpret65. 
The question, yet unsolved, is how to screen for TB during anti-TNFα therapy: in a regular 
schedule or according to epidemiology? performing a TST or and an IGRA test? Use the usual 
or other cut-off values? It is generally accepted that TST is considered positive at an induration 
of five or more millimetres for immunosuppressed patients and at 10 or more millimetres for 
persons not immunosuppressed. Similarly, should we work on establishing a different cut-off 
value for IGRA tests for persons under immunomodulators or biological drugs? Moreover, in 
populations that have been BCG vaccinated at birth lower rates of IGRA positivity compared 
with non-vaccinated population have been elicited66. This situation may introduce an extra 
difficulty for IGRA tests results for those that were BCG vaccinated. Thus, it seems that several 
answers to the question of rescreening for TB will be expectable, according to the specificities 
of the studied population. According to our results and the actual knowledge, we would 
suggest screening for TB during anti-TNF therapies (and other drugs with risk of TB 
reactivation) for those with a negative TB screening at baseline. The suggestion is to do this 
first screening after six to nine months of therapy, due to the higher risk of infection in the first 
months of ant-TNFα therapy, and then annually. A TST would probably be the best strategy. 
When TST is not available,  an IGRA test should be used. After some negative screenings, the 
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decision to maintain TB screening yearly would be tailor made, according to demographic and 
clinical issues. Male gender and long duration of the immunomediated disease should favour 
the screening. A TST conversion or a positive test result in the absence of active disease will be 
an indication for latent TB treatment; at this point ongoing TB surveillance will be based on 
clinical and epidemiological factors.  
Considering other granulomatous infections, a real risk was found in our cohort. There 
is no simple way to reduce the risk, as several and different factors may be in its origin, such 
as: food (considering Salmonella, Listeria, Brucella), air-borne (Legionella, Coxiella), 
environment (Coxiella, endemic mycosis, Nocardia). Thus, accuracy for an early diagnosis is 
essential.  
Persistent intestinal colonization with Nocardia nova was a concern in our cohort as 
therapeutic immunosuppression may give rise to dissemination and disease. Although, the 
need of screening for these agents is not stated. 
Intracellular infections caused by herpes DNA virus may reactivate due to several 
reasons, including immunomodulators (thiopurines analogs and glucosteroids, for instance) 
and biological therapies67,68. Some of these infections may be severe, as were the case of 
disseminated herpes simplex virus infection and varicella pneumonia described in our cohort. 
Besides varicella-zoster and zoster vaccines and the prophylactic prescription of acyclovir 
under certain drugs (like tofacitinib and alemtuzumab) no other prevention is available. The 
risk may be higher under particular situations that may occur together, such as 
immunosuppressive drugs in association, advanced age, rheumatic diseases. Define a score for 
risk concerning herpes virus reactivation would be useful to stratify risk and proceed according 
to it. 
Considering the global risk of infection, outside TB screening and latent TB treatment, 
counselling concerning food, environment and travel is useful. Also, screening for infections 
(such as hepatitis A, B and C, HIV, syphilis, DNA-virus), immunizations (against Pneumococcus, 
influenza, hepatitis A and B, Bordetella pertussis among others) and sometimes prophylaxis 
(for Pneumocystis jirovecii disease and herpes infection) are important issues to reduce this 
risk. A practical protocol to guide this workup is included in this work. 
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9. Final remarks 
 
In the real world of a Portuguese cohort of adult patients treated with 
immunmodulators and biological drugs, mainly anti -TNF α, TB was the core of opportunistic 
and severe diseases. The majority of these TB cases likely resulted from reactivation of latent 
infection. Therefore, screening and treatment of latent TB is essential to mitigate the risk. The 
suboptimal performance of the tests used for TB diagnosis (TST and IGRA’s), including  
uncertainties concerning the interpretation of test results in patients already 
immunosuppressed, the complexity of these patients considering the disease to be treated, 
comorbidities, age and epidemiology, among other variables, increase the difficulties of latent 
TB diagnosis. 
Of note, the sensitivity of TST was higher than the sensitivity of IGRA’s (and that from 
T-SPOT.TB higher than that from QFT-GIT) in all the situations: before anti-TNF α or in the 
switch of anti -TNF α and even during anti-TNF α prescription. Against the actual mainstream, 
probably would be advisable to wait for better tests for latent TB diagnosis before replace the 
old TST. 
Concerning latent TB field, we need a high predictive test able to identify those at 
highest risk of progressing to active TB and for whom therapy for latent TB would be 
beneficial. Such a test may probably rely on the identification of biomarkers or biosignatures, 
especially gene expression signatures that are still far from the real word69.  
For now, on the setting of TB screening during anti-TNF α prescription, based in our 
results we suggest to screen on the first years of treatment all TST and IGRA’s negative 
patients and then  do the screening in a tailor based way, according to perceived TB risk. 
Considering that TST and IGRA’s are not optimal tests, both should be considered. Although, 
due to shortage of TST one will probably rely on IGRA tests; T-SPOT.TB, due to higher 
sensitivity in our sample than Quantiferon, should probably be preferred. 
There is also risk of other severe granulomatous and intracellular infections, as we 
have diagnosed in our cohort. Thus, precautions concerning food and environment risks are 
important, as well as an active surveillance of signals and symptoms, to treat infections as 
early as possible. 
We believe that screening, prevention of infection (including immunizations) and 
counselling in patients about to star biologics or immunomodulators due to an auto 
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inflammatory disease is a useful task on infectious risk mitigation, and we herein propose a 
practical protocol. 
Finally, the risk of infection may be even partially unknown for the most recent 
therapies, so is crucial to maintain an attentive surveillance. 
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